Adenoid的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列懶人包和總整理

Pediatric Otolaryngology for Primary Care

為了解決Adenoid的問題，作者 這樣論述：

This popular AAP manual provides expert help for virtually any commonly encountered pediatric ENT condition.Pediatric Otolaryngology is the first place to turn for expert help with the myriad ear, nose, and throat disorders. From adenopathy to ankyloglossia, ear infection to epistaxis, and from stri

dor to speech disorders, look here for the state of the art across the length and breadth of pediatric ENT disorders. Pediatric Otolaryngology delivers the precise level of detail primary care providers require. The book's practice-focused, case-based presentation streamlines patient problem-solving

. "How to" clinical pearls help you master key diagnosis and treatment procedures. This must-have manual includes more than 100 high-quality photos and illustrations to aid with diagnosis.KEY FEATURESThree new chapters: Complications of Chronic Eustachian Tube Dysfunction: Retractions, Perforations,

Cholesteatoma; Feeding Disorders/Ankyloglossia; and Pediatric TracheostomyUpdated guidelines for treatment of otitis media with effusionUpdated guideline on newborn hearing assessment and cytomegalovirus causationUpdated recommendations to treat intractable drooling Scott R Schoem, MD, MBA, FAAP

is a graduate of Georgetown University School of Medicine. He performed his surgical internship and otolaryngology residency at the National Naval Medical Center in Bethesda, MD and his fellowship in pediatric otolaryngology at National Children’s Medical Center in Washington, DC. He founded and has

been Director of Otolaryngology at Connecticut Children’s Medical Center in Hartford, CT since 1999. Dr Schoem is a Professor of Clinical Otolaryngology at UCONN, the Past President of the CT ENT Society, and the Past Chair of the Section on Otolaryngology - Head and Neck Surgery of the American Ac

ademy of Pediatrics (AAP). He is the President-elect of the CT AAP state chapter. Dr Schoem is active in children’s healthcare advocacy and policy. He is a board member of ENT PAC at the American Academy of Otolaryngology - Head and Neck Surgery. He has extensive experience lobbying both at the stat

e and federal level to members of Congress. David Darrow, MD, DDS, FAAP is a Professor of Otolaryngology and Pediatrics at the Eastern Virginia Medical School, and an attending otolaryngologist at the Children’s Hospital of The King’s Daughters in Norfolk, VA. After receiving degrees in both dentist

ry and medicine, Dr Darrow completed residency in otolaryngology at the University of California, San Diego and a fellowship in pediatric otolaryngology at the Children’s Memorial Hospital in Chicago. Dr Darrow’s primary clinical and research interests are in the areas of otitis media, tonsillitis,

and vascular birthmarks. He is the founder and co-director of the EVMS Center for Hemangiomas and Vascular Birthmarks, a multidisciplinary treatment program for patients with these disorders. He has lectured locally and nationally on proper diagnosis and management of middle ear disease in children.

He has also written extensively on indications for tonsil and adenoid surgery. He has served on panels that developed guidelines for pediatric tonsillectomy, pediatric acute sinusitis, and infantile hemangiomas. Dr Darrow is the immediate past president of the Society for Ear, Nose, and Throat Adva

nces in Children. He is a former Chair of the American Academy of Pediatrics Section on Otolaryngology and has served on the executive committee of the American Society of Pediatric Otolaryngology.

Adenoid進入發燒排行的影片

運用奈米鉑-金雙金屬顆粒增強近紅外光吸收於癌症光熱治療法

為了解決Adenoid的問題，作者吳鈞裕 這樣論述：

摘要 iiAbstract iii圖目錄 vii表目錄 ix誌謝 x第一章 前言 11.1研究背景與目的 11.2實驗流程圖 2第二章 文獻回顧與理論 32.1奈米材料 32.1.1奈米鉑 32.1.2奈米金 32.2光熱治療 42.3卵巢癌 42.3.1卵巢癌診斷 52.3.2卵巢癌的治療 62.4乳腺癌 62.4.1乳腺癌的診斷 72.4.2乳腺癌的治療 8第三章 實驗材料與分析方法 103.1實驗材料與藥品 103.2實驗儀器 113.3材料製備 1

23.4材料分析 123.4.1穿透式電子顯微鏡及能量色散-X-射散光譜(Energy Dispersive Spectroscopy)分析 123.4.2材料粒徑大小統計 123.5感應耦合電漿光學發射光譜儀分析(ICP-OES Assay) 133.6細胞實驗 133.6.1培養基製備 133.6.2細胞解凍 153.6.3細胞培養 153.6.4細胞計數 153.6.5細胞保存 163.7細胞存活率分析(MTT Assay) 163.7.1 含有分散劑之Pt/Au NPs及Au NPs毒性分析 173.7.2未含有分

散劑之Pt/Au NPs及Au NPs毒性分析 173.8光熱治療 183.8.1 Pt/Au NPs及Au NPs光熱治療 183.8.2 Pt/Au NPs及Au NPs對細胞之光熱治療 183.9動物實驗 193.9.1腫瘤動物模式誘發與建立 193.9.2光熱治療動物 203.9.3動物犧牲組織與採樣 203.9.4動物組織切片與病理分析 203.10實驗統計分析 20第四章 結果與討倫 214.1 TEM表面形貌觀察與粒徑分析 214.1.1 Pt/Au NPs及Au NPs離心前後之形貌 214.1.2

Pt/Au NPs及Au NPs不同濃度之形貌 214.2感應耦合電漿光學發射光譜儀分析(ICP-OES Assay) 224.3細胞存活率分析(MTT Assay) 224.3.1 Pt/Au NPs及Au NPs含有分散劑對SKOV-3之MTT試驗及T-test分析 234.3.2 Pt/Au NPs及Au NPs含有分散劑對JC之MTT試驗及T-test分析 234.3.3 Pt/Au NPs及Au NPs未含有分散劑對SKOV-3之MTT試驗及T-test分析 244.3.4 Pt/Au NPs及Au NPs未含有分散劑對JC之MTT試驗及T-tes

t分析 254.4光熱治療 264.4.1 Pt/Au NPs及Au NPs升溫取線 264.4.2 Pt/Au NPs及Au NPs對SKOV-3光熱治療試驗及T-test分析 274.4.3 Pt/Au NPs及Au NPs對JC光熱治療試驗及T-test分析 284.5動物實驗 294.5.1動物體重觀察 294.5.2動物光熱治療升溫取線 294.5.3動物腫瘤體積估算 304.5.4動物組織病理切片 31第五章 結論 33參考文獻 34附件 88

Journal & Tracker: Healing Cervical Adenoid Basal Carcinoma: The 30 Day Raw Vegan Plant-Based Detoxification & Regeneration Jour

為了解決Adenoid的問題，作者Formation, Health 這樣論述：

Investigation of the Induction of Prostate Cancer Mutagenesis and Development of A Novel Method for Early Detection of Prostate Cancer with Nanoimaging

為了解決Adenoid的問題，作者Titus Ime Ekanem 這樣論述：

AbstractProstate cancer is a slow growing cancer which affects elderly males worldwide; although 10 percent of the younger population is reported at risk. There have been many hypotheses regarding its origin, but to date no actual cause has been adduced. However, there are many associated risk fact

ors some of which include environmental factors, social and dietary habits. Cooking food at very high temperature generates acrylamide and glycidamide, chemicals previously reported to be mutagenic. Previous studies have reported association of acrylamide with colorectal, brain, lung and ovarian can

cers. It was associated with treatment failures in advanced diseases due to drug resistance. Most conventional chemotherapeutic and hormonal agents have not been able to reduce the high rate of morbidity and mortality associated with the metastatic disease. Since most of these patients have lowered

immunity; recent studies show that stimulation of their immune system could improve their ultimate response to treatment. Although drugs to target the immune checkpoint have been developed for treatment of prostate cancer, there is no appreciable improvement in the overall patient survival, probably

due to poor penetration of the drug to the appropriate sites. Its current detection methods are nonspecific. With a view to developing a novel detection method for its early detection, we have identified androgen receptor as a molecular target as it is overexpressed in about 80 percent of castrate-

resistant prostate cancer. We therefore worked with the aim to synthesize AuNRs@SPIOs-PEG-AR-ab nanoprobes to early detect prostate cancer formation, mutagenesis, and trace the route of metastasis employed by prostate cancer cells in vivo using the nanoprobes. To overcome treatment failures, we have

conjugated CTLA-4-CA21 aptamer to the gold-coated iron oxide nanoprobes which can detect and kill prostate cancer cells even after metastasis has occurred.Method: We synthesized gold-nanorods and iron oxide nanoparticles, functionalized them with organosilanes due to their large surface area to vol

ume ratio, specific optical, electronic, magnetic and chemical properties including high surface energy, conjugated/coupled with the androgen receptor antibody, the CTLA-4-CA21 aptamer and the FITC/CyTE777 dyes. The nanoprobes were characterized, then used to assess cellular uptake efficiency, cytot

oxicity and their ability to detect prostate cancer cells in vitro were assessed using nanoimaging techniques on a more malignant variant of the prostate cancer cell line induced in our laboratory with glycidamide and in nude mice.Results: The nanoprobes have the wavelength maxima at 805 nm, the TEM

images dimensions of gold nanorods and iron oxide nanocrystals were 200 ± 30 nm and 80 nm respectively. Glycidamide-treated cells showed evidence of more nanoprobes uptake, the nanoprobes has low level of toxicity. They have the potential to enter the cancer cells and target androgen receptors in t

he nuclei as shown by the deconvolution/confocal microscopy, near infrared fluorescence imaging and IVIS imaging results. These glycidamide transformed-cells showed reduced doubling time, epithelial mesenchymal transition with invadopodia. They were more proliferative, formed spheroids with invadopo

dia in matrigel invasive assays, and induced changes in androgen receptor, prostate specific antigen, and annexin A2 protein expressions which have been associated with aggressiveness in prostate cancer. The CTLA4-CA21 nanoprobes have the wavelength maxima at 803 nm, the TEM images dimensions which

would enhance movement in the circulation. They show evidence of cell death, and the inhibitory effects on cell proliferation were dose-dependent on LNCaP, DU145, PC3 and BPH cells, with the greatest inhibition at 14.77 picomolar concentration. The near infrared imaging on the live cells showed mar

ked cellular disruptions and apoptotic changes in the cancer cells.Conclusion: With the wavelength maxima of 805 nm and 803 nm for AR nanoprobes and aptamer nanoprobes respectively which are within the “NIR imaging window”, our gold-shell iron oxide-core nanoprobes can penetrate deep tissues and ove

rcome autofluorescence from tissues observed in the visible light region. The aggressiveness such as short doubling time, epithelial mesenchymal transition, formation of invadopodia, and upregulated levels of invasive biomarkers, exhibited by the glycidamide-treated prostate cancer cells compared to

the parental cell lines could be due to the upregulation of androgen receptor promoted by glycidamide. With these great potentials the AuNRs@SPIOs-PEG-AR-ab nanoprobes can be used non-invasively in the early detection of prostate cancer. The inhibitory effects of the aptamer on cell proliferation w

ere dose-dependent at picomolar concentration as well as the marked cellular disruptions and apoptotic changes in the live cancer cells in the near infrared imaging have proved the potency of the modified DNA CTLA-4 aptamer. Therefore they have great potential for use in the treatment of advanced pr

ostate cancers and those associated with drug resistance.Keywords: Glycidamide, prostate cancer cells, mutagenesis, early detection, nanoprobes, nanoimaging .